Medicinal drugs have been used extensively since the advent of civilization to cure or treat or ease the symptoms. Medications have been taken in a variety of ways—by swallowing, by inhalation, by absorption through the skin, or by injection. The method or process of administering them to achieve the desired therapeutic effect is called drug delivery. Drug delivery technologies modify drug release profile, absorption, distribution, and elimination for the benefit of improving product efficacy and safety, as well as patient convenience and adherence.
The traditional mode of drug delivery incorporates non-invasive peroral routes i.e. through the mouth, the topical route- through the skin, the transmucosal route-through the nose, eye, vagina, or rectum, and inhalation routes.
The limitations of traditional drug delivery systems can be encountered with a novel drug delivery system which is a modern approach to drug delivery. A novel drug delivery system cures a particular disease by targeting exactly the affected zone inside a patient's body and transporting the drug to that area. Pharmaceutical scientists have shifted their focus on designing different drug delivery systems for medicines using a scientific approach by delivering the components to the target area in a novel manner. It not only provides better efficacy and increases patient compliance, by avoiding repeated administration but also helps to reduce toxicity and hence increases the therapeutic value of the drug. As a result, NDDS enhances the bioavailability of the drug and helps it in capturing as well as to remaining in the market.
The novel drug delivery market size has been valued at approximately USD 11 billion in 2022 and is estimated to reach USD 40 billion by 2035 growing at a robust CAGR of 21% during the forecast period, i.e., 2023-2035.
Some of the trends positively impacting the market growth are-
Some of the trends negatively impacting the market growth are-
The major companies operating in the novel drug delivery systems market are Mylan N.V., Novartis International AG, Sanofi S.A, GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, and others.
The novel drug delivery system is the new face of drug administration which has a lot of potential for growth and development. This growth and development when integrated with research and innovation can reach new heights of profitability. But there are many challenges with novel drug delivery that need to be addressed like the difficulty of conducting clinical research, development of simple bioassays for biological standardization, toxicological evaluation methods’ development, investigation of their sites of absorption, and safety evaluation, legal and regulatory aspects of drugs, etc. With the overcoming of these hurdles, the potential of the market can be reached fruitfully.